Key Highlights of the Phase 2a Emodepside Trial
High Efficacy at Low Doses
Emodepside demonstrated significant anthelmintic activity starting at the lowest tested dose of 5 mg, which yielded a predicted cure rate of 78.3%. This marks a substantial improvement over the 0% cure rate observed in the placebo group.
Optimal Dosing Identified
The dose-response curve for emodepside reached a clinical plateau at 15 mg, achieving an 89.1% cure rate. This performance is statistically comparable to the current gold standard, ivermectin, which showed an 88.0% cure rate in the same study population.
Simplified Fixed-Dose Regimen
One of the most significant findings is the potential for a weight-independent, fixed-dose administration. This could simplify mass drug administration (MDA) programs in endemic regions where weighing every patient is often impractical.
Manageable Safety Profile
While adverse events were common shortly after administration—most notably somnolence and transient visual disturbances—they were predominantly mild and self-limiting, with no serious adverse events reported.
Background: The Persistent Burden of Strongyloidiasis
Strongyloidiasis, caused by the parasitic nematode Strongyloides stercoralis, remains one of the most neglected of the neglected tropical diseases (NTDs). It is estimated to infect between 300 million and 600 million people worldwide, primarily in tropical and subtropical regions with poor sanitation. Unlike many other soil-transmitted helminths, S. stercoralis has a unique life cycle involving autoinfection, which allows the parasite to persist within a human host for decades. In immunocompromised individuals, this can lead to the life-threatening hyperinfection syndrome or disseminated strongyloidiasis, which carries a mortality rate exceeding 80% if untreated.
Currently, ivermectin is the primary treatment recommended by the World Health Organization (WHO). While effective, ivermectin is often used as a single dose, which may not achieve complete clearance in all patients. Furthermore, the global reliance on a single drug class raises significant concerns regarding the potential development of drug resistance, as seen in veterinary medicine. There is an urgent clinical need for novel anthelmintic agents with different mechanisms of action to diversify the treatment landscape.
Emodepside: From Veterinary Success to Human Clinical Development
Emodepside is a semi-synthetic derivative of PF1022A, a fermentation product of the fungus Mycelia sterilia. It belongs to the cyclooctadepsipeptide class, a group of chemicals with a distinct mechanism of action compared to macrocyclic lactones like ivermectin. Emodepside acts on the presynaptic latrophilin-like receptors and calcium-activated potassium channels (Slo-1) at the neuromuscular junction of nematodes. This leads to inhibitory signaling, resulting in the paralysis and death of the parasite.
Originally developed and widely used in veterinary medicine (often in combination with praziquantel for feline and canine deworming), emodepside has recently been transitioned into human clinical trials. Its broad-spectrum activity against various nematodes, including those responsible for onchocerciasis and soil-transmitted helminthiasis, makes it a prime candidate for treating S. stercoralis.
Study Design: A Dose-Ranging Exploration in Endemic Laos
This phase 2a trial was conducted in the Champhone district of Savannakhet province, Laos, a region highly endemic for S. stercoralis. The study employed a randomized, parallel-group, placebo-controlled, single-blind design to evaluate the efficacy and safety of ascending doses of emodepside.
Participant Selection and Randomization
The trial screened 820 individuals, eventually enrolling 202 adults aged 18–60 years. Eligibility required the provision of three stool samples with a mean of at least 0.75 larvae per gram, confirmed via sextuplicate Baermann assays—the gold standard for Strongyloides diagnosis due to its higher sensitivity compared to the Kato-Katz technique.
Participants were randomly assigned in a 1:1:1:1:1:1:1:1 ratio to eight groups:
1. Placebo
2. Ivermectin (standard 200 μg/kg dose)
3. Emodepside 5 mg
4. Emodepside 10 mg
5. Emodepside 15 mg
6. Emodepside 20 mg
7. Emodepside 25 mg
8. Emodepside 30 mg
Endpoints and Masking
The primary efficacy endpoint was the cure rate (CR) 14–21 days post-treatment. Safety was assessed through clinical examinations and adverse event (AE) monitoring at 3, 24, 72 hours, and 14 days after drug administration. Laboratory technicians and clinical staff were masked to treatment assignments to ensure objective outcome assessment.
Results: Defining the Optimal Efficacy Threshold
The findings, published in The Lancet Infectious Diseases, demonstrate a clear dose-response relationship for emodepside.
Comparative Cure Rates
The placebo group showed a 0% cure rate, confirming the lack of spontaneous clearance during the study period. In contrast, even the lowest dose of emodepside (5 mg) showed a predicted cure rate of 78.3% (95% CI 59.4–89.9). As the dose increased, so did the efficacy, until reaching a plateau at 15 mg with a cure rate of 89.1% (95% CI 81.6–93.7).
When compared to the active control, ivermectin (CR 88.0%; 95% CI 68.8–97.5), the 15 mg dose of emodepside provided nearly identical therapeutic outcomes. Higher doses (20 mg to 30 mg) did not significantly increase the cure rate further, suggesting that 15 mg may be the optimal dose for balancing efficacy and tolerability.
Dose-Response Modeling
Statistical modeling indicated that the Emax (maximum effect) was reached at relatively low doses. This suggests that emodepside is highly potent against S. stercoralis larvae. The consistency of the results across the 15–30 mg range supports the feasibility of a fixed-dose approach for adults, regardless of body weight.
Safety and Tolerability: Transient Post-Treatment Effects
Emodepside was generally well-tolerated, though the frequency of adverse events increased with the dose. Most AEs occurred within the first 3 to 24 hours after treatment and resolved without medical intervention.
Common Adverse Events
1. Somnolence: This was the most frequent AE, reported by 36% of participants in the 15 mg group and up to 68% in the 30 mg group.
2. Visual Disturbances: Vision blur and impairment were noted, particularly at higher doses (up to 44% in the 30 mg group).
3. Dizziness: Reported by approximately 8% to 28% of participants across the emodepside groups.
Importantly, these neurological and visual symptoms were transient. There were no serious adverse events (SAEs) or events requiring hospitalization. The safety profile at the optimal 15 mg dose was considered acceptable for further clinical development.
Expert Commentary: Bridging the Gap in Neglected Tropical Disease Care
The success of this phase 2a trial is a significant milestone for tropical medicine. Experts note that the transition of emodepside from veterinary to human use represents a successful example of drug repurposing. The weight-independent dosing is particularly attractive for clinicians working in resource-limited settings. In traditional MDA programs, calculating weight-based dosages for ivermectin or albendazole can be a logistical hurdle; a single-tablet, fixed-dose regimen for adults could drastically increase the efficiency of public health interventions.
However, some limitations must be acknowledged. The study was single-blind (investigators were not masked), and it was conducted in a specific geographical population in Laos. Further research is needed to determine the efficacy of emodepside in children, pregnant women, and patients with severe hyperinfection syndrome. Additionally, while the 15 mg dose performed well, the transient visual side effects will need to be carefully explained to patients in larger-scale deployments to ensure compliance and prevent alarm.
Conclusion: A New Chapter in Anthelmintic Therapy
The phase 2a trial of emodepside provides robust evidence that this novel compound is a highly effective and safe alternative to ivermectin for the treatment of Strongyloides stercoralis. By achieving a cure rate of approximately 89% at a 15 mg dose, emodepside offers a potent tool to combat parasitic resistance and improve the lives of millions. As the global health community strives toward the WHO 2030 targets for NTDs, emodepside stands out as a promising candidate for inclusion in the next generation of anthelmintic strategies.
Funding and Clinical Registry
This study was funded by the European Research Council (ERC) and the Uniscientia Foundation. The trial is registered at ClinicalTrials.gov under the identifier NCT06373835.
References
1. Taylor L, Many S, Jeanguenat H, Hattendorf J, Sayasone S, Keiser J. Efficacy and safety of ascending doses of emodepside in comparison with ivermectin in adults infected with Strongyloides stercoralis in Laos: a phase 2a, dose-ranging, randomised, parallel-group, placebo-controlled, single-blind clinical trial. Lancet Infect Dis. 2025 Nov;25(11):1254-1264. doi: 10.1016/S1473-3099(25)00255-5.
2. World Health Organization. Guideline: preventive chemotherapy to control soil-transmitted helminth infections in at-risk population groups. Geneva: World Health Organization; 2017.
3. Nutman TB. Human Strongyloidiasis: A Net-Neglected Tropical Disease. Clin Infect Dis. 2017;64(3):360-362.
